AdvaMed Names Scott Whitaker CEO and President

WASHINGTON, Feb. 18, 2016 /PRNewswire-USNewswire/ -- The Board of Directors of the Advanced Medical Technology Association (AdvaMed) announced today that Scott Whitaker will be its next president and chief executive officer effective April 4, 2016.

Whitaker joins AdvaMed, the world's leading association for medical technology companies, having served most recently as chief operating officer of the Biotechnology Innovation Organization (BIO).

"We are very pleased that Scott has agreed to lead AdvaMed at a time of unprecedented change in health care," said AdvaMed Board Chairman Vincent A. Forlenza, chairman, CEO and president of BD. "Medical technology companies are at the forefront of developing solutions that improve patient outcomes and enable the delivery of high-quality, cost-effective care. However, continued progress in these areas depends on ensuring a strong innovation ecosystem. Scott has a proven track record as an association leader, and we believe he has the vision to set the course for AdvaMed's future."

"It is a tremendous privilege to join AdvaMed and represent such an innovative and life changing industry.  Given the many health care challenges throughout the world, it is critical that we work together to create a policy and regulatory environment that will allow this industry to continue to discover, develop and deliver innovative medical technologies to patients. It is essential that patients everywhere have full access to the benefits of medical technology. I look forward to working with these amazing companies and telling the story of life changing innovation," said Whitaker. 

As BIO's chief operating officer, Whitaker managed all aspects of the organization's day-to-day operations, including advocacy, policy, communications and non-dues revenue business. As president of the BIO International Convention, Whitaker oversaw the world's largest gathering of the biotechnology industry. Prior to joining BIO, Whitaker served in key leadership roles at the Department of Health and Human Services, including as chief of staff and assistant secretary for legislation.

AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.

SOURCE AdvaMed

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.